Skip to content

Study · Not a test of the peptide alone · 2024

1 result

FDG PET in a Patient on a GLP-1 Agonist/Insulin Secretagogue.

Oldan JD, Landman PG, Schroeder JA, Khandani AH, Solnes LB, Lee CB, Rowe SP

Clinical nuclear medicine20 Jun 2024Cited by 2 (Europe PMC)

PMID38914020 (opens in a new tab)DOI10.1097/rlu.0000000000005318 (opens in a new tab)PepBankPUB-38914020
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome

    In one patient, use of a GLP-1 receptor agonist medication presumptively led to muscular and myocardial FDG uptake that complicated PET scan interpretation.

    In plain wordsIn one patient, a GLP-1 type medication probably caused extra muscle and heart uptake on an FDG PET scan, making it hard to read.

    Peptide
    Semaglutide
    Outcome
    IncreaseFDG PET muscular and myocardial uptake
    Study

    n = 1

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    We demonstrate a case where a patient's use of such a medication presumptively led to muscular and myocardial uptake, complicating scan interpretation considerably.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.